Building Value in Clinical Repurposing, February 24, 2020

On February 24, 2020 at Findacure's Drug Repurposing for Rare Diseases 2020 symposium in London, Barbara Goodman presented on the opportunity to build value through clinical drug repurposing.



ABC7 Newsviews: April 12, 2020

ABC7 News Anchor Judy Hsu interviews Cures Wiithin Reach's Barbara Goodman in this two-part video about drug repurposing trials underway now to help find possible treatments for the COVID19 pandemic.

With no treatment or vaccine for COVID-19, clinical trials are underway to see if drugs that are already on the market can be "repurposed" to treat patients with the virus.  This idea of "repurposing" isn't new. The global healthcare community is working together in unprecedented ways to treat patients and learn from each other.  Many opportunities are underway using already approved drugs in clinical trials to treat COVID-19 patients, providing evidence based medicine to clinicians. President and Chief Operating Officer Barbara Goodman joined Newsviews to talk to the latest developments.

pharmatechoutlook logoPharma Tech Outlook

Dr. Bruce Bloom

August 2018

Drug repurposing has been a part of therapy discovery in medicine for as long as there have been drugs- even before the arrival of commercial "drugs" - when healers first repurposed nature's compounds for medical purposes. For this article we will define repurposing as testing drugs that are already approved for human use to find new uses in new diseases.

Repurposed therapies used by physicians often resulted from some type of serendipity, which curious physicians and scientists examined further. Their observations were clinically tested, and the results were published for off-label use or commercialization of the repurposed therapies. Other repurposed therapies arose from desperate attempts by physicians and scientists to find anything that could help suffering patients, as was the case with many repurposed cancer therapies. Read the full article here

ABC7 Eyewitness News
June 21, 2018

A Northwest Indiana woman told she may never get pregnant again after being diagnosed with cancer is beating the odds. She says it's all thanks to the ongoing research of drug repurposing to treat diseases with no cure. In this case, she calls it a miracle drug. While pregnant with her first child, Karrie was diagnosed with a rare blood cancer. "It's the whole terrifying process of being diagnosed with a cancer," said Karrie Schwartz who was diagnosed with polycythemia vera. Karrie opted not to have chemotherapy which would've ended her hopes of having another baby. The couple from Munster, Indiana, was determined to find another way.

viagra image

The Washington Post
Aimee Swartz
May 13, 2018


When a medication being developed to treat a heart condition gave patients erections, drugmakers knew they had a winner — not for angina, but for erectile dysfunction. That drug is now known as Viagra.

Figuring out that a drug developed for one ailment can be effective for another was once a matter of chance. In the case of Viagra, for example, the discovery emerged by observing an unintended but beneficial side effect. Now, technological and scientific advances are allowing researchers to rely more on science and less on luck in hopes of cutting the time and expense involved in getting new treatments to patients.

Frontiers in Oncology

J. Javier Hernandez, Michael Pryszlak, Lindsay Smith, Connor Yanchus, Naheed Kurji, Vijay M. Shahani and Steven V. Molinski

November 14, 2017

logo frontonco

The repositioning or “repurposing” of existing therapies for alternative disease indications is an attractive approach that can save significant investments of time and money during drug development. For cancer indications, the primary goal of repurposed therapies is on efficacy, with less restriction on safety due to the immediate need to treat this patient population. This report provides a high-level overview of how drug developers pursuing repurposed assets have previously navigated funding efforts, regulatory affairs, and intellectual property laws to commercialize these “new” medicines in oncology. This article provides insight into funding programs (e.g., government grants and philanthropic organizations) that academic and corporate initiatives can leverage to repurpose drugs for cancer.

In addition, we highlight previous examples where secondary uses of existing, Food and Drug Administration- or European Medicines Agency-approved therapies have been predicted in silico and successfully validated in vitro and/or in vivo (i.e., animal models and human clinical trials) for certain oncology indications. Finally, we describe the strategies that the pharmaceutical industry has previously employed to navigate regulatory considerations and successfully commercialize their drug products. These factors must be carefully considered when repurposing existing drugs for cancer to best benefit patients and drug developers alike. See full article.

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 12, Issue 10

By Cynthia A. Challener

Oct 04, 2017

Compared to traditional drug discovery approaches, drug repurposing, repositioning, and rescue can be faster and cheaper

Although drug repurposing has been receiving growing attention in recent years, drug companies have taken this approach, at least serendipitously, for decades. Viagra, originally developed as an angina treatment, is one of the most well-known examples. Today many groups are focused on identifying new indications for existing drugs including academic researchers; nonprofits such as Cures Within Reach; and government institutions including the National Center for Advancing Translational Sciences in the United States and the UK Medical Research Council. Other drug repurposing research ventures include public-private partnerships like the Center for Drug Repurposing (operated jointly by Ariel University [Israel] and Drug Rediscovery Ltd) and the Drug Repurposing Hub (a collaboration between the Broad Institute Cancer Program, the Center for the Development of Therapeutics, and the Connectivity Map group); and companies such as Biovista, GVK Bio, and NuMedii. In 2012, it was estimated that drug repurposing, repositioning, and rescue (DRPx) efforts accounted for 30% of FDA-approved new drug products (1). In addition, in 2015, Biovista President and Co-founder Aris Persidis reported that these drugs accounted for approximately 25% of pharmaceutical industry revenues (2).

Read the full article!

ABC7 Eyewitness News

June 27, 2017


CHICAGO (WLS) -- Honors were handed out Tuesday night for those who have made a difference in the lives of rare disease patients. The organization Cures Within Reach held its annual Global Health Repurposing Awards ceremony. ABC7 Eyewitness News' Judy Hsu served as emcee.

ABC7 Eyewitness News

By Judy Hsu

June 27, 2017

A potential medical breakthrough happening in Chicago is literally saving limbs.

An experimental treatment for patients with chronic poor circulation, often brought on by heart disease or diabetes, is part of a new push for drug repurposing -- finding new cures with existing medicine.

Like millions of Americans, Curtis Richardson suffers from poor circulation in his legs.

"That can manifest as problems like pain when you walk, pain in your feet at night, ultimately wounds that won't heal," said Dr. George Havelka, assistant professor of surgery at the University of Illinois-Chicago.

For Richardson, walking became nearly impossible.

"Pain was so bad had me in tears sometimes," Richardson said.

His condition, up until now, had few medical options.

"The natural history of that is needing surgery or possibly even amputation," Havelka said.

However, Havelka and Dr. Darwin Eton, of the University of Illinois Hospital, are trying a new approach - a clinical study that involves no surgery and no hospital stay.

The treatment uses an existing drug for cancer patients that mobilizes the body's own stem cells and a standard compression device. Havelka said "hopefully helps those stem cells hone in to where the disease is at and allowing the patient to build up new circulation and improve the blood flow."

The breakthrough treatment took a decade of research, with promising results.

PILMAN- A Tapan Ray Website on Healthcare

April 17, 2017

By Tapan Ray

The prices of new cancer drugs are increasingly becoming unsustainable across the world, and more so in India. A sizable number of poor and even middle-income patients, who spend their entire life’s savings for the treatment of this dreaded disease, is pushed towards extreme economic hardship. Their plight in India would continue to remain so, till Universal Health Care (UHC) comes into force, as enunciated in the National Health Policy 2017.

Thus, the delivery of affordable and equitable cancer care poses one of India’s greatest public health challenges. Public expenditure on cancer in India remains below US$ 10 per person, as compared with more than US$ 100 per person in high-income countries. The May 2014 paper, published in ‘The Lancet Oncology’, analyzed this concern in detail.

Read the full article

Laboratory Equipment

April 17, 2017

By Erin O'Neill

When scientists with the pharmaceutical company Pfizer started clinical trials in 1991 on a chemical compound named UK-92480, they aimed to show the drug’s potential therapeutic benefit for a cardiovascular condition caused by restricted blood flow to the heart muscle.
Less than two years later, hope that the compound, now better known as sildenafil, could treat angina began to fade.

But the drug wasn’t shelved. Rather, scientists began exploring whether one of the drug’s reported side effects—erections—could help men suffering from another condition.

The U.S. Food and Drug Administration in 1998 approved sildenafil, under the brand name Viagra, for the treatment of erectile dysfunction. In its first year on the market, sales of the little blue pill topped $1 billion.

Read the full article

Pharmaceutical Patent Analyst

March 1, 2017

Dr. Bruce Bloom

There are a number of generic drugs that might be useful in treating tuberculosis, but will they ever get to the patients who need them? They might, but not without a lot of help. There are intellectual property issues, endpoint issues, cost of research issues, economic incentive issues, preclinical validation issues, “who is in charge” issues and many more. It is clear that repurposed generic drugs have the potential to make a safe, effective, quick and affordable impact on a global disease of poverty such as tuberculosis. But without the economic incentives that are usually in place for drug development, can we muster the scientific, economic and governmental support to bring them to the patients? 

Read full article

Driving Insights to Action

February 27, 2017

Drug repurposing and reformulation leverage already expended costs for compounds that failed to reach the market for one disorder, to develop reformulated or repurposed drugs for a different condition in less time and with less cost. How will repurposing disrupt the current market? Where are the stress points in delivering repurposed products to patients?

A special DIAmond panel discussion titled Drug Repurposing: Where Will It Take Us?, chaired by President and Chief Scientific Officer of Cures Within Reach Dr. Bruce Bloom, will explore this topic at our DIA 2017 Annual Meeting. “If you can repurpose a generic drug for some unmet medical need and you’re charging the same price for that drug as any other generic in use, you’re liable to be creating a good therapy at a very reasonable cost,” Dr. Bloom explains in this exclusive podcast. “If you’re able to do that, the net health care cost benefit is almost always significantly positive.”

Click here to listen to the podcast interview

Click here to sign up for our eNewsletter today!

Please include your Full Name* and Email Address*


If the link above doesn't work, please contact our Admin support at with your Full Name and Email Address to sign up!


Cures Within Reach

134 N. LaSalle, #1130
Chicago, IL 60602

All funds donated to Cures Within Reach may be tax deductible for federal income tax purposes. 

Partnership for Cures DBA Cures Within Reach is recognized by the IRS as a 501(c)3 tax-exempt not-for-profit organization, tax ID 20-3620169.


Friday the 10th. Copyright 2018 Cures Within Reach.